ES2217396T3 - Utilizacion de il-7 en el tratamiento de las enfermedades auto-inmunes, en particular, la diabetes mellitus insulinodependiente. - Google Patents
Utilizacion de il-7 en el tratamiento de las enfermedades auto-inmunes, en particular, la diabetes mellitus insulinodependiente.Info
- Publication number
- ES2217396T3 ES2217396T3 ES97907134T ES97907134T ES2217396T3 ES 2217396 T3 ES2217396 T3 ES 2217396T3 ES 97907134 T ES97907134 T ES 97907134T ES 97907134 T ES97907134 T ES 97907134T ES 2217396 T3 ES2217396 T3 ES 2217396T3
- Authority
- ES
- Spain
- Prior art keywords
- autoimmune
- cells
- treatment
- disease
- auto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010002586 Interleukin-7 Proteins 0.000 title claims abstract description 68
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 28
- 206010012601 diabetes mellitus Diseases 0.000 title description 30
- 102000000704 Interleukin-7 Human genes 0.000 claims abstract description 67
- 229940100994 interleukin-7 Drugs 0.000 claims abstract description 65
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 31
- 230000007547 defect Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 39
- 108090000978 Interleukin-4 Proteins 0.000 claims description 30
- 230000001363 autoimmune Effects 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 102100032912 CD44 antigen Human genes 0.000 claims description 13
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 230000006735 deficit Effects 0.000 claims description 11
- 230000017307 interleukin-4 production Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 7
- 210000004241 Th2 cell Anatomy 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 206010062269 Adrenalitis Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 206010040628 Sialoadenitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000005963 oophoritis Diseases 0.000 claims description 2
- 230000003950 pathogenic mechanism Effects 0.000 claims description 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000001050 sialadenitis Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 37
- 102000004388 Interleukin-4 Human genes 0.000 description 29
- 229940028885 interleukin-4 Drugs 0.000 description 28
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 229940090044 injection Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 108010066312 streptavidin-tricolor Proteins 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9602501 | 1996-02-28 | ||
FR9602501A FR2745185B1 (fr) | 1996-02-28 | 1996-02-28 | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2217396T3 true ES2217396T3 (es) | 2004-11-01 |
Family
ID=9489676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97907134T Expired - Lifetime ES2217396T3 (es) | 1996-02-28 | 1997-02-26 | Utilizacion de il-7 en el tratamiento de las enfermedades auto-inmunes, en particular, la diabetes mellitus insulinodependiente. |
Country Status (13)
Country | Link |
---|---|
US (2) | US6713053B1 (fr) |
EP (1) | EP0883406B1 (fr) |
JP (1) | JP3138481B2 (fr) |
AT (1) | ATE264112T1 (fr) |
AU (1) | AU1929397A (fr) |
BR (1) | BR9707776A (fr) |
DE (1) | DE69728654T2 (fr) |
DK (1) | DK0883406T3 (fr) |
ES (1) | ES2217396T3 (fr) |
FR (1) | FR2745185B1 (fr) |
NO (1) | NO321569B1 (fr) |
PT (1) | PT883406E (fr) |
WO (1) | WO1997031648A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
AR080291A1 (es) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
EP2791322A1 (fr) | 2011-12-12 | 2014-10-22 | Cell Medica Limited | Procédé de propagation de cellules t |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
US20150010519A1 (en) | 2012-02-09 | 2015-01-08 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
CA2923314A1 (fr) | 2013-09-05 | 2015-03-12 | Sanford-Burnham Medical Research Institute | Modulation des lymphocytes t .gamma..delta. |
WO2017049291A1 (fr) | 2015-09-18 | 2017-03-23 | Baylor College Of Medicine | Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5032396A (en) * | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
US5229115A (en) * | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
US5474769A (en) * | 1991-03-08 | 1995-12-12 | Sterling Winthrop Inc. | Treatment of microbial infection by monocyte stimulation with interleukin-7 |
US6576236B1 (en) * | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
-
1996
- 1996-02-28 FR FR9602501A patent/FR2745185B1/fr not_active Expired - Lifetime
-
1997
- 1997-02-26 WO PCT/FR1997/000343 patent/WO1997031648A1/fr active IP Right Grant
- 1997-02-26 DE DE69728654T patent/DE69728654T2/de not_active Expired - Lifetime
- 1997-02-26 US US09/125,168 patent/US6713053B1/en not_active Expired - Lifetime
- 1997-02-26 PT PT97907134T patent/PT883406E/pt unknown
- 1997-02-26 DK DK97907134T patent/DK0883406T3/da active
- 1997-02-26 AU AU19293/97A patent/AU1929397A/en not_active Abandoned
- 1997-02-26 AT AT97907134T patent/ATE264112T1/de active
- 1997-02-26 BR BR9707776A patent/BR9707776A/pt not_active Application Discontinuation
- 1997-02-26 EP EP97907134A patent/EP0883406B1/fr not_active Expired - Lifetime
- 1997-02-26 ES ES97907134T patent/ES2217396T3/es not_active Expired - Lifetime
- 1997-02-26 JP JP09530667A patent/JP3138481B2/ja not_active Expired - Lifetime
-
1998
- 1998-08-26 NO NO19983917A patent/NO321569B1/no not_active IP Right Cessation
-
2004
- 2004-03-26 US US10/810,109 patent/US20040180037A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PT883406E (pt) | 2004-08-31 |
NO983917L (no) | 1998-10-28 |
WO1997031648A1 (fr) | 1997-09-04 |
US6713053B1 (en) | 2004-03-30 |
JP3138481B2 (ja) | 2001-02-26 |
DE69728654D1 (de) | 2004-05-19 |
BR9707776A (pt) | 1999-07-27 |
FR2745185B1 (fr) | 1998-05-15 |
EP0883406B1 (fr) | 2004-04-14 |
NO983917D0 (no) | 1998-08-26 |
FR2745185A1 (fr) | 1997-08-29 |
US20040180037A1 (en) | 2004-09-16 |
NO321569B1 (no) | 2006-06-06 |
ATE264112T1 (de) | 2004-04-15 |
EP0883406A1 (fr) | 1998-12-16 |
DK0883406T3 (da) | 2004-08-02 |
AU1929397A (en) | 1997-09-16 |
JPH11508605A (ja) | 1999-07-27 |
DE69728654T2 (de) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2173953T5 (es) | Uso del il-12 y antagonistas del il-12 para la fabricacion de una composicion farmaceutica para el tratamiento de enfermedades autoinmunes. | |
Shimizu et al. | Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity | |
Chen et al. | Inductive events in oral tolerance in the TCR transgenic adoptive transfer model | |
Tanaka et al. | A pivotal role of IL-12 in Th1-dependent mouse liver injury | |
JPH02503919A (ja) | 自己抗原の経口投与による自己免疫疾患の治療法 | |
Stallmach et al. | An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo | |
Maas et al. | Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2 | |
JP2000509604A (ja) | サプレッサー細胞集団を生成するためのインターロイキン―10の使用 | |
US5624938A (en) | Use of chloroquine to treat multiple sclerosis | |
JPH05508663A (ja) | 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物 | |
JPH07505892A (ja) | 多型性クラスiimhcアロペプチドを用いた増殖反応の抑制及び寛容の誘発 | |
ES2217396T3 (es) | Utilizacion de il-7 en el tratamiento de las enfermedades auto-inmunes, en particular, la diabetes mellitus insulinodependiente. | |
Pankewycz et al. | A protective NOD islet‐infiltrating CD8+ T cell clone, IS 2.15, has in vitro immunosuppressive properties | |
Sugihara et al. | Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. Characterization of thyroiditis-inducing T cell lines and clones derived from thyroid lesions. | |
CN101126076A (zh) | TGF-β诱导的调节T细胞及其形成方法和应用 | |
Talpaz et al. | The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients | |
Piguet | GVHR elicited by products of class I or class II loci of the MHC: analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy. | |
Ju et al. | Inducer T-cell-mediated killing of antigen-presenting cells | |
Ten Berge et al. | Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. | |
ES2224105T3 (es) | Cadena alfa soluble de receptores de celulas t y derivados utilizados como agentes profilacticos y terapeuticos para enfermedades autoinmunes. | |
WO2006052660A9 (fr) | Blocage du recepteur il-7 pour supprimer l'immunite | |
Ranges et al. | In vivo immunomodulation by monoclonal anti-L3T4: 1. Effects on humoral and cell-mediated immune response | |
Ito et al. | Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice | |
WO2005004789A2 (fr) | Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative ou quantitative de l'adn extracellulaire du sang | |
Sun et al. | Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice |